Callahan Advisors LLC Lowers Stock Holdings in STERIS plc $STE

Callahan Advisors LLC reduced its stake in STERIS plc (NYSE:STE) by 5.4% during the 4th quarter, HoldingsChannel reports. The firm owned 46,164 shares of the medical equipment provider’s stock after selling 2,640 shares during the period. Callahan Advisors LLC’s holdings in STERIS were worth $11,703,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of STE. Jones Financial Companies Lllp boosted its stake in shares of STERIS by 46.1% in the first quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after buying an additional 349 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of STERIS by 32.3% in the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock valued at $55,015,000 after buying an additional 59,264 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of STERIS by 16.1% in the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock valued at $522,000 after buying an additional 319 shares in the last quarter. Woodline Partners LP boosted its stake in shares of STERIS by 40.0% in the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after buying an additional 2,372 shares in the last quarter. Finally, Jane Street Group LLC boosted its stake in shares of STERIS by 38.9% in the first quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock valued at $4,695,000 after buying an additional 5,803 shares in the last quarter. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the transaction, the director directly owned 705 shares of the company’s stock, valued at $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.07% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, April 16th. Finally, KeyCorp decreased their price target on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.67.

STERIS Stock Up 0.5%

STE opened at $215.51 on Thursday. The business’s fifty day moving average is $218.56 and its two-hundred day moving average is $242.42. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.54 and a current ratio of 2.09. The company has a market cap of $21.14 billion, a price-to-earnings ratio of 27.18 and a beta of 0.95. STERIS plc has a one year low of $195.14 and a one year high of $269.44.

STERIS (NYSE:STE) last released its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.59 billion. During the same period last year, the firm earned $2.74 earnings per share. The business’s revenue was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Analysts anticipate that STERIS plc will post 11.18 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, June 8th. STERIS’s payout ratio is 31.78%.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.